Glucotrack, Lōkahi Therapeutics Close Merger to Form AI-Driven Public Biotech Platform

Glucotrack and Lōkahi Therapeutics have officially completed a strategic business combination, the companies announced, establishing a Lōkahi-controlled public platform designed to accelerate drug discovery and development through artificial intelligence. The deal marks a pivotal shift in how the newly combined entity intends to source and advance therapeutic assets in an increasingly competitive biotech landscape.

At the heart of the transaction is Lōkahi's proprietary ai²-driven platform, which the company says enables capital-efficient identification, development, and advancement of drug assets. By pairing that technology with Glucotrack's existing public market infrastructure, the combined company gains immediate access to public capital markets — a strategic advantage that management argues will underpin a repeatable growth model without the prolonged timelines typical of traditional biotech IPO routes.

Read more BlackRock's GIP to Acquire Majority Stake in Summit Ridge Energy →

The structure of the deal positions the combined company to pursue what executives describe as a disciplined, scalable strategy: use AI to surface and de-risk therapeutic candidates, then leverage public market access to fund their progression. That combination, if executed as planned, could allow the organization to move faster and more cost-effectively than peers relying on conventional venture-backed pipelines.

The business combination reflects a broader trend in biotech, where smaller public shell companies or device firms are increasingly being used as reverse-merger vehicles by therapeutics companies eager to sidestep lengthy and expensive traditional IPO processes. Lōkahi's AI-centric approach adds a technology differentiator to what might otherwise be viewed as a straightforward financial maneuver.

Continue reading at GlobalNewswire.